Natera, Inc.

NasdaqGS:NTRA

Market Cap

USD 23.47 B

Share Price

USD 164.16

Avg Daily Volume

1,477,653

Change (1 day)

-4.49%

Change (1 year)

47.43%

Change (YTD)

3.70%

Natera, Inc. Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2025: 4.09

Natera, Inc. Current Ratio is 4.09 for the Trailing 12 Months (TTM) ending March 31, 2025, a -0.65% change year over year. Current ratio represents the short-term liquidity measurement, showing current assets' coverage of liabilities. Higher ratio implies better ability to meet short-term obligations.
  • Natera, Inc. Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2024 was 4.11, a 13.14% change year over year.
  • Natera, Inc. Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 3.63, a -23.05% change year over year.
  • Natera, Inc. Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 4.72, a 7.73% change year over year.
  • Natera, Inc. Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 4.38, a 63.54% change year over year.
Key data
Date Current Ratio Interest Coverage Ratio Return on Capital Employed (ROCE) Return on Equity (ROE)
Market news
Loading...
NasdaqGS: NTRA

Natera, Inc.

CEO Mr. Steven Leonard Chapman
IPO Date July 1, 2015
Location United States
Headquarters 13011 McCallen Pass Building A
Employees 4,424
Sector 🏥 Health Care
Industries
Description

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.

Similar companies

BSX

Boston Scientific Corporation

USD 104.29

0.16%

SHL.DE

Siemens Healthineers AG

USD 54.76

0.58%

GEHC

GE HealthCare Technologies Inc.

USD 72.75

1.07%

LH

Laboratory Corporation of America Holdings

USD 258.70

-1.46%

BAX

Baxter International Inc.

USD 30.61

0.07%

TORNTPHARM.NS

Torrent Pharmaceuticals Limited

USD 37.11

-1.05%

ICLR

ICON Public Limited Company

USD 145.91

-1.77%

RGC

Regencell Bioscience Holdings Limited

USD 21.73

-5.32%

ASND

Ascendis Pharma A/S

USD 173.00

-3.41%

EXAS

Exact Sciences Corporation

USD 51.92

1.47%

CTEC.L

ConvaTec Group Plc

USD 3.96

0.77%

300832.SZ

Shenzhen New Industries Biomedical Engineering Co., Ltd.

USD 8.00

0.06%

GH

Guardant Health, Inc.

USD 49.90

-0.18%

DIA.MI

DiaSorin S.p.A.

USD 109.19

-0.66%

3347.HK

Hangzhou Tigermed Consulting Co., Ltd.

USD 4.54

-5.44%

LNTH

Lantheus Holdings, Inc.

USD 80.55

-0.49%

688617.SS

APT Medical Inc.

USD 41.26

1.54%

TMDX

TransMedics Group, Inc.

USD 128.58

-3.06%

ADMA

ADMA Biologics, Inc.

USD 17.60

-1.40%

LAURUSLABS.NS

Laurus Labs Limited

USD 7.78

-0.11%

IPCALAB.NS

Ipca Laboratories Limited

USD 15.81

0.19%

INSP

Inspire Medical Systems, Inc.

USD 132.00

-0.42%

600566.SS

Hubei Jumpcan Pharmaceutical Co., Ltd.

USD 3.93

1.22%

002603.SZ

Shijiazhuang Yiling Pharmaceutical Co., Ltd.

USD 1.97

-0.21%

PFIZER.NS

Pfizer Limited

USD 65.60

1.28%

300676.SZ

BGI Genomics Co., Ltd.

USD 6.92

-0.27%

ERIS.NS

Eris Lifesciences Limited

USD 18.85

-0.41%

LIVN

LivaNova PLC

USD 45.87

-0.35%

300529.SZ

Jafron Biomedical Co.,Ltd.

USD 2.99

0.64%

VIMIAN.ST

Vimian Group AB (publ)

USD 4.23

-3.41%

VCYT

Veracyte, Inc.

USD 26.45

-1.60%

BAVA.CO

Bavarian Nordic A/S

USD 26.28

-0.67%

0853.HK

MicroPort Scientific Corporation

USD 1.09

1.19%

VITR.ST

Vitrolife AB (publ)

USD 14.21

-1.42%

QDEL

QuidelOrtho Corporation

USD 28.11

-1.95%

NVCR

NovoCure Limited

USD 17.32

1.91%

HRMY

Harmony Biosciences Holdings, Inc.

USD 31.57

-1.53%

603882.SS

Guangzhou Kingmed Diagnostics Group Co., Ltd.

USD 3.99

0.81%

CERT

Certara, Inc.

USD 10.86

1.59%

ARQT

Arcutis Biotherapeutics, Inc.

USD 14.47

0.98%

002287.SZ

Tibet Cheezheng Tibetan Medicine Co., Ltd.

USD 3.14

-0.23%

688289.SS

Sansure Biotech Inc.

USD 2.86

-0.42%

INDGN.NS

Indegene Limited

USD 6.78

0.44%

ADPT

Adaptive Biotechnologies Corporation

USD 11.98

12.49%

603567.SS

Heilongjiang ZBD Pharmaceutical Co., Ltd.

USD 1.68

0.72%

002020.SZ

Zhejiang Jingxin Pharmaceutical Co., Ltd.

USD 1.80

-0.78%

300026.SZ

Tianjin Chase Sun Pharmaceutical Co.,Ltd

USD 0.52

-0.59%

605507.SS

Guobang Pharma Ltd.

USD 2.73

-1.40%

688016.SS

Shanghai MicroPort Endovascular MedTech Co., Ltd.

USD 12.29

-0.52%

BHVN

Biohaven Ltd.

USD 14.33

-2.98%

StockViz Staff

June 27, 2025

Any question? Send us an email